# KEYNOTE-427 (NCT02853344)

> Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: locally advanced/metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02853344
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Pembrolizumab
- Enrollment: 275
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on KEYNOTE-427 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 31
- YouTube: 18
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-427-nct02853344

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02853344", "email": "<work email>"}; the inbox owner confirms by the emailed link.